Meningococcal disease: A review on available vaccines and vaccines in development

Minerva Medica

Volumn 98, Issue 5, 2007, Pages 575-589

  Broker M ^a   Fantoni, S ^b  

^a Novartis Vaccine   (Germany)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Antibodies; Immune system; Meningococcal vaccine; Vaccine, conjugate; Vaccines, combined

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; BIVALENT AC VACCINE COMBINATION; CARRIER PROTEIN; CROSS REACTING MATERIAL 197; DIPHTHERIA TOXIN; DIPHTHERIA TOXOID; MENINGOCOCCUS VACCINE; NERVE CELL ADHESION MOLECULE; OLIGOSACCHARIDE; OUTER MEMBRANE PROTEIN; POLYSACCHARIDE VACCINE; SEROGROUP A CONJUGATE VACCINE; SEROGROUP B MENINGOCOCCAL VACCINE; SEROGROUP C CONJUGATE VACCINE; SEROGROUP W135 CONJUGATE VACCINE; SEROGROUP Y CONJUGATE VACCINE; TETANUS TOXOID; TETRAVALENT ACW135 COMBINATION VACCINE; UNCLASSIFIED DRUG; VESICLE VACCINE;

ADSORPTION; BACTERICIDAL ACTIVITY; CELLULAR IMMUNITY; CLINICAL STUDY; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG MANUFACTURE; EPIDEMIC; GENOME ANALYSIS; HIGH RISK POPULATION; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; INCIDENCE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PATHOGENESIS; PREVENTION AND CONTROL; PREVENTIVE HEALTH SERVICE; PROPHYLAXIS; PUBLIC HEALTH PROBLEM; REVIEW;

ANTIGENS, BACTERIAL; CELL WALL; HUMANS; ITALY; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS, SEROGROUP B; NEISSERIA MENINGITIDIS, SEROGROUP C; POLYSACCHARIDES, BACTERIAL; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 36949037783     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997;337:970-6.
2. Rosenstein NE, Bradley A, Perkins BA, Stephens DS, Popovic T, Hughes J. Meningococcal disease. N Engl J Med 2001;344:1378-88.
3. Noah N, Henderson B. Surveillance of bacterial meningitis in Europe 1999/2000. The European Bacterial Meningitis Surveillance Project. Available from: http://www.phls.co.uk
4. nd edition) Geneva: World Health Organization; 1998. Available from: http://www.who.int/emc-documents/meningitis/whoemcbac983chtml
5. Swartley JS, Marfin A A, Edupuganti S, Liu LJ, Cieslak P, Perkins B et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci 1997;94:271-6.
6. Vogel U, Claus H, Frosch M. Rapid serogroup switching in Neisseria meningitidis. N Engl J Med 2000;342:219-20.
7. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998;176:870-4.
8. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987;138:4402-7.
9. MacLennon JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants. A randomized controlled trial. JAMA 2000;283:2795-801.
10. Choo S, Zuckermann J, Goilav C, Hatzmann E, Everard J, Finn A et al. Immunogenicity and reactogenicity of a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine 2000;18:2686-92.
11. MacDonald NM, Halperin SA, Law BJ, Forest B, Danzig LE, Granoff DM et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers. JAMA 1998;280:1685-9.
12. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001;183:160-3.
13. Borrow R, Goldblatt D, Andrews N, Southern J, Ashton, L, Deane S et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 2002;186:1353-7.
14. McVernon J, MacLennon J, Buttery J, Oster P, Danzig L, Moxon ER et al. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J 2002;21:747-53.
15. MacDonald NE, Halperin SA, Law BJ, Danzig L, Granoff DM et al. Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine? Am J Med Ass 2000;283:1826-7.
16. Maiden MCJ, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002;359:1829-30.
17. Salisbury D. Introduction of a conjugate meningococcal type C vaccine programme in the UK. J Paediatr Child Health 2001;37 Suppl:34-7.
18. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001;358:195-6.
19. Miller E, Salisbury D, Ramsey M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C in the UK: a success story. Vaccine 2001;20 Suppl 1:58-67.
20. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002;51:717-22.
21. Trotter CL, Ramsey ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007;31:101-7.
22. Esposito S, Corbellini B, Bosis S, Pugni L, Tremolati E, Tagliabue C et al. Immunogenicity, safety and tolerability of meningococcal C CRM197 conjugate vaccine administered 3, 5 and 11 months post-natally to preterm and full-term infants. Vaccine 2007;25:4889-94.
23. Trotter C, Edmunds WJ. Reassessing the cost-effectiveness of meningococcal serogroup conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Making 2006;26:38-47.
24. De Wals P. Immunization strategies for the control of serogroup C meningococcal disease in developed countries. Expert Rev Vaccines 2006;5:269-75.
25. Shao Z, Li W, Ren J, Liang X, Xu L, Diao B et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet 2006;367:419-23.
26. Kadlubowski M. Invasive meningococcal disease at a military base in Warsaw, January 2007. Eurosurveillance 2007;12:2-5.
27. Boisier P, Nicolas P, Djibo S, Taha M-K, Jeanne I, Mainassara HB et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007;44:657-63.
28. Sistema Informatizzato Malattie Infettive (Surveillance Infectious Diseases System of Istituto Superiore di Sanità). Dati di sorveglianze sulle meningiti. Available from: http://www.simi.iss.it/dati.htm
29. Piano Nationale Vaccini (aggiornamento 2005). Italian National Immunization Plan 2005-2007. Available from: http://www.ministerosalute.it/imgs/ C_17_normativa_526_ulterioriallegati_ulterioreallegato_0_alleg.pdf
30. Epicentro: National Epidemiology- Surveillance and Health Promotion Centre. Available from: http://www.epicentro.iss.it/problemi/vaccinazioni/ CalendariRegionali.pdf
31. th 2006.. Available from: http://www.ecdc.eu.mt/Healm_topics/ VI/VI_newsletter.html
32. Jennings HJ, Roy R, Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice using an N-propionylated B polysaccharide-tetanus toxoid vaccine. J Immunol 1986;37:1708-13.
33. Sarvamangala JN, Devi SJ, Robbins JB, Schneerson R. Antibodies to poly (2?8)-·-N-acetylneuraminic acid and poly (2 9)- -N-acetylneuraminic acid are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc Natl Acad Sci USA 1991;88:7175-9.
34. Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004;22:1087-96.
35. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes, J et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomised controlled trial in Chile. JAMA 1999;281:1520-7.
36. De Moraes JC, Perkins BA, Camargo MCC, Hidalgo NTR, Barbosa HA, Sacchi CT et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074-8.
37. Taha M-K, Zarantonelli ML, Alonso J-M, Meyer Næss L, Holst J, Feiring B et al. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine 2007;25:2537-8.
38. De Kleijn ED, de Groot R, Labadie J, Lafeber AB, van den Dobbelsteen G, van Arphen L et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 2000;18:1456-66.
39. Martin SL, Borrow R, van der Ley P, Dawson M, Fox AJ, Cartwright KAV et al. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 2000;18:2476-81.
40. Baker MG, Martin DR, Kieft C, Lennon D. A 10 year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J Paediatr Child Health 2001;37 Suppl:13-9.
41. Lystad A, Aasen S. The epidemiology of meningococcal disease in Norway 1975-1991. NIPH Ann 1991,14:57-66.
42. O'Hallahan J, Lennon D, Oster P. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J 2004;23 Suppl:293-8.
43. Nøkleby H, Aavitsland P, O'Hallahan JO, Ferring B, Tilman S, Oster P. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 2007;25:3080-4.
44. West D, Reddin K, Matheson M, Heath R, Funnell S, Hudson M et al. Recombinant Neisseria meningitidis transferring binding protein a protects against experimental meningococcal infection. Infect Immun 2001;69:1561-7.
45. Cadieux N, Plante M, Rioux CR, Hamel J, Brodeur BR, Martin D et al. Bacterial and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun 1999;67:4955-9.
46. Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitis surface protein confers protection against experimental infection. J Exp Med 1997;185:1173-83.
47. Halperin SA, Langley JM, Smith B, Wunderli P, Kaufman L, Kimura A et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal Nsp A vaccine in healthy adults. Vaccine 2007;25:450-7.
48. Wedege E, Bolstad K, Aase A, Herstad TK, McCallum L, Rosenqvist E et al. Functional and specific antibody responses in adult volunteers vaccinated with two different meningococcal serogroup B outer membrane vesicle vaccines in New Zealand. Clin Vaccine Immunol 2007 May 9; [Epub ahead of print]
49. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000;287:1809-15.
50. Rappuoli, R. Reverse vaccinology. Curr Opin Microbiol 2000;3:445-50.
51. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000;287:1816-20.
52. Jacobsson S, Thulin S, Mölling P, Unemo M, Comanducci M, Rappuoli R et al. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 2006;24:2161-8.
53. Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Arico B, Capecchi B et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002;195:1445-54.
54. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L et al. A universal vaccine for the serogroup B meningococcus. Proc Natl Acad Sci USA 2006;103:10834-9.